Alnylam Pharmaceuticals: all 84 studies

Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)RecruitingNCT07636811Phase 2
• A Study to Evaluate ALN-6222 in Participants With ObesityRecruitingNCT07624071Phase 1
• HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBRecruitingNCT07575308Phase 2
• A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranRecruitingNCT07553442Phase 2
• A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusRecruitingNCT07465224Phase 2
• A Study to Evaluate ALN-2232 in Participants With ObesityRecruitingNCT07463846Phase 1/2
• DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingRecruitingNCT07358078
• A Study to Evaluate ALN-4285 in Adult Healthy VolunteersRecruitingNCT07295717Phase 1
• TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyRecruitingNCT07223203Phase 3
• A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseRecruitingNCT07214727Phase 1
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruitingNCT07181109Phase 3
• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyRecruitingNCT07052903Phase 3
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyEnrolling by invitationNCT06679946Phase 3
• A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaRecruitingNCT06600321Phase 1
• A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseRecruitingNCT06585449Phase 1
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADRecruitingNCT05231785Phase 1
• Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramRecruitingNCT05040373
• ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)RecruitingNCT04883905
• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)RecruitingNCT04561518
• A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionCompletedNCT06423352Phase 1/2Results posted
• A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate LevelsTerminatedNCT05161936Phase 2Results posted
• Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)CompletedNCT05103332Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionCompletedNCT04936035Phase 2Results posted
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyActive, not recruitingNCT04153149Phase 3Results posted
• A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedNCT04152200Phase 3Results posted
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)CompletedNCT03997383Phase 3Results posted
• A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedNCT03905694Phase 3Results posted
• Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantCompletedNCT03862807Phase 3Results posted
• A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)TerminatedNCT03841448Phase 2Results posted
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)CompletedNCT03759379Phase 3Results posted
• A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1CompletedNCT03681184Phase 3Results posted
• An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedNCT03350451Phase 2Results posted
• ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)CompletedNCT03338816Phase 3Results posted
• A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)CompletedNCT02949830Phase 1/2Results posted
• Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1CompletedNCT02706886Phase 1/2Results posted
• The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver TransplantCompletedNCT02595983Phase 2Results posted
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)CompletedNCT02510261Phase 3Results posted
• A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNHCompletedNCT02352493Phase 1/2Results posted
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)CompletedNCT02319005Phase 3Results posted
• A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac AmyloidosisCompletedNCT02292186Phase 2Results posted
• The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)CompletedNCT01961921Phase 2Results posted
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisCompletedNCT01960348Phase 3Results posted
• Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) AmyloidosisCompletedNCT01617967Phase 2Results posted
• A Study to Evaluate ALN-4915 in Adult Healthy VolunteersActive, not recruitingNCT07535606Phase 1
• A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMActive, not recruitingNCT06845202Phase 1/2
• A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersCompletedNCT06675565Phase 1
• A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Active, not recruitingNCT06659640Phase 1/2
• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyActive, not recruitingNCT06393712Phase 2
• Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With PolyneuropathyActive, not recruitingNCT06360289
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)CompletedNCT06272487Phase 2
• A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DMTerminatedNCT05761301Phase 1/2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy SubjectsCompletedNCT05661916Phase 1
• Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With CardiomyopathyNo longer availableNCT05505838
• A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With GoutTerminatedNCT05256810Phase 1/2
• BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Active, not recruitingNCT04982393
• A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT04565717Phase 1
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A MutationCompletedNCT04201418
• Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Approved for marketingNCT04125472
• Expanded Access Protocol of Givosiran for Patients With Acute Hepatic PorphyriaApproved for marketingNCT04056481
• A Study to Evaluate ALN-AGT01 in Patients With HypertensionCompletedNCT03934307Phase 1
• A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) DiseaseTerminatedNCT03774784
• A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseTerminatedNCT03767829Phase 1/2
• INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHPTerminatedNCT03547297
• A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)CompletedNCT03505853Phase 1
• A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnNCT03303313Phase 2
• Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)Approved for marketingNCT02939820
• A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) InfectionTerminatedNCT02826018Phase 1
• A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy SubjectsCompletedNCT02797847Phase 1
• A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseTerminatedNCT02503683Phase 1
• A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)CompletedNCT02452372Phase 1
• A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)CompletedNCT02314442Phase 1
• DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac AmyloidosisCompletedNCT02252653
• EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)CompletedNCT02240784
• A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy VolunteersCompletedNCT02053454Phase 1
• Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac AmyloidosisCompletedNCT01981837Phase 2
• A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy VolunteersCompletedNCT01814839Phase 1
• Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer SubjectsCompletedNCT01559077Phase 1
• Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)CompletedNCT01437059Phase 1
• Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 TreatmentCompletedNCT01158079Phase 1
• Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) AmyloidosisCompletedNCT01148953Phase 1
• Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)CompletedNCT01065935Phase 2
• Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver InvolvementCompletedNCT00882180Phase 1
• Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)CompletedNCT00658086Phase 2
• Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial VirusCompletedNCT00496821Phase 2

← Alnylam Pharmaceuticals overview and focus areas